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Abstract
Background: Mutations in the TP53 gene are extremely common and occur very early in the progression of serous 
ovarian cancers. Gene expression patterns that relate to mutational status may provide insight into the etiology and 
biology of the disease.
Methods: The TP53 coding region was sequenced in 89 frozen serous ovarian cancers, 40 early stage (I/II) and 49 
advanced stage (III/IV). Affymetrix U133A expression data was used to define gene expression patterns by mutation, 
type of mutation, and cancer stage.
Results: Missense or chain terminating (null) mutations in TP53 were found in 59/89 (66%) ovarian cancers. Early stage 
cancers had a significantly higher rate of null mutations than late stage disease (38% vs. 8%, p < 0.03). In advanced 
stage cases, mutations were more prevalent in short term survivors than long term survivors (81% vs. 30%, p = 0.0004). 
Gene expression patterns had a robust ability to predict TP53 status within training data. By using early versus late stage 
disease for out of sample predictions, the signature derived from early stage cancers could accurately (86%) predict 
mutation status of late stage cancers.
Conclusions: This represents the first attempt to define a genomic signature of TP53 mutation in ovarian cancer. 
Patterns of gene expression characteristic of TP53 mutation could be discerned and included several genes that are 
known p53 targets or have been described in the context of expression signatures of TP53 mutation in breast cancer.
Background
The TP53 tumor suppressor gene encodes a transcription
factor that plays a critical role in regulating cell cycle pro-
gression, DNA repair, and cell death. TP53 is the most
frequently altered gene in human cancers and loss of
functional p53 protein occurs in a majority of epithelial
ovarian cancers. Ovarian cancers with serous histology
account for about two-thirds of the incident disease and
these cases usually present at an advanced stage leading
to a very high mortality rate. In studies in which full gene
sequencing has been performed, 60-70% of both early
and advanced stage serous ovarian cancers harbor TP53
mutations [1,2]. In contrast, other histological subtypes
of epithelial ovarian cancer that more commonly present
at an early stage (endometrioid, clear cell, mucinous) have
a much lower incidence of TP53 mutations [2]. Recently,
TP53 mutations have been found in serous tubal intraepi-
thelial carcinomas, usually in the context of "prophylac-
tic" surgery in BRCA1 or BRCA2 mutations carriers. This
suggests that TP53  mutation is an early event in the
development of many serous cancers of the ovary, fallo-
pian tube, and peritoneum [3-5].
It is possible that inactivation of the TP53  gene, or
pathway, may be a requisite event in the development of
serous cancers. In cancers that appear to retain the wild
type coding sequence, p53 may be inactivated by other
mechanisms (e.g., TP53 promoter or splicing alterations,
MDM2 overexpression); or other genes that are regulated
by  TP53  may be altered obviating the need for direct
inactivation of TP53. Alternatively, it is possible that the
presence or absence of TP53 mutation in serous cancers
may be one factor underlying the clinical heterogeneity of
the disease with respect to stage, response to therapy, and
outcome. Because p53 plays an important role in regula-
tion of DNA damage response and repair as well as apop-
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tosis, it has been postulated that inactivation of p53 in
ovarian cancer is associated with resistance to cytotoxic
therapy. However, a review of the extensive literature on
p53 in ovarian cancer does not support a consistent rela-
tionship between TP53 mutation and/or overexpression
and response to therapy or survival [6-8]. The absence of
a clear association between TP53  alterations and out-
come may reflect the complexity that underlies response
to therapy or may be an indication that mutations in the
coding sequence represent only a subset of the functional
p53 alterations.
Since the p53 protein is a transcriptional activator,
identification of an expression signature related to its
activity has been pursued previously. Further, a number
of genes have been demonstrated to be p53 inducible
under various conditions and/or contain putative p53
response elements. However, since many of these experi-
ments were performed either by transfection of wild type
p53 or introduction of DNA damage, direct translation of
this information to expression patterns in a given tissue
that exists in a steady-state has been difficult. From
breast cancer expression data, two separate groups found
signatures related to the TP53 mutational status of the
tumor [9,10]. While these signatures are somewhat con-
sistent in the two studies, the complication in relating
these expression patterns directly to p53 status is that
mutations in breast cancer are much more likely to occur
within a certain intrinsic subtype (basal), also defined by
gene expression [11,12]. In the current study we attempt
to derive, validate, and investigate the nature of a p53
expression signature in primary serous ovarian cancers
and to relate those to signatures described in breast and
other types of cancers.
Methods
Patient specimens
The specimens and relevant clinicopathological informa-
tion were obtained with patient consent and used under
protocols approved by the Duke University Institutional
Review Board. Flash frozen specimens of 89 invasive
serous ovarian cancers obtained at the time of initial sur-
gery were utilized including 49 advanced stage (III/IV)
and 40 early stage (I/II) cases (Table 1). All advanced
stage cases and 7 of the early stage cases were obtained
from the Duke Gynecologic Oncology Tumor bank and
the remaining 33 early stage cases were obtained from
either the Gynecologic Oncology Group (GOG) or
Memorial Sloan Kettering Cancer Center. Treatment and
outcome data were not available for the GOG cases.
Gene expression analysis
All expression data were previously generated from flash
frozen tumor samples the Affymetrix U133A arrays and
converted to MAS5 values [13]. The primary microarray
data are available at http://data.genome.duke.edu/earlys-
tageovc. We analyzed gene expression from formalin-
fixed, paraffin-embedded samples in 38 of the advanced
stage cancers using the Illumina Whole Genome DASL
assay (cDNA-mediated annealing, selection, extension,
and ligation) corresponding to 24,000 genes. Two slides
containing 5 μm-thick sections of tumor were used for
RNA extraction with the Ambion Recover All Total
Nucleic Acid Isolation kit following the manufacturer's
instructions. A total of 200 ng of RNA was then run on
the Illumina Whole-Genome DASL Assay with the
HumanRef-8 Bead Chip.
TP53 gene sequencing
The mutational status of TP53 was examined by nucle-
otide sequencing of TP53 cDNA for all tumors in this
study (Tumor Mutation Information, Additional File 1).
Total RNA was isolated from flash frozen tissue speci-
mens using RNA Stat-60 (Teltest; Friendswood, TX).
cDNA was generated from one microgram of RNA using
Roche (AMV) First Strand cDNA Synthesis Kit and ran-
dom hexamer primers according to the manufacturer's
recommendations (Roche Applied Science; Indianapolis,
IN). PCR amplification was performed in a 25 μl reaction
volume using 2.5 μl cDNA, 1.25 units Platinum Taq
(Invitrogen; Carlsbad, CA), 0.2 mM each dNTP, 3 mM
MgCl2, 5 μl Qiagen's Q Solution (Valencia, CA) and 0.4
μM each of forward primer F1 (5'-GAC ACG CTT CCC
TGG ATT-3') and reverse primer R1 (5'-AGG GTT CAA
AGA CCC AAA AC-3'). Cycling conditions were 94°C for
3 min, 35 cycles of 94°C for 30 sec, 61°C for 30 sec and
72°C for 2 min, followed by a final 5 min extension at
72°C. Amplicons were purified using Qiagen's MinElute
PCR Purification Kit and sequenced in both directions
using Big Dye Terminator Sequencing (Applied Biosys-
tems; Foster City, CA). Sequencing primers included F1
listed above, F2 (5'-TTT TGC CAA CTG GCC AAG-3'),
R2 (5'-GGT GGG AGG CTG TCA G-3'), and R3 (5'-GAG
TCT TCC AGT GTG ATG ATG G-3'). The TP53 refer-
ence sequence NM_000546 was used for comparison to
identify sequence variants present on the forward and
reverse strands. Ambiguous results were resolved by
sequencing of genomic DNA.
Statistical Analysis
Data was imported into GeneSpringGx where all normal-
izations and analyses were performed. Initial filtering of
probe sets was accomplished by applying an upper and
lower threshold of expression (75-20000) of the raw
M A S 5  v a l u e s  b e f o r e  r o w  a n d  c o l u m n  c e n t e r i n g  f o r  a t
least 15 of the 89 arrays. This resulted in 13,622 probes
carried forward in common for all subsequent analyses.
An unpaired T test was applied for each comparison with
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tiple comparisons using the method of Benjamini-Hoch-
berg [14]. Fold changes for the probes are expressed
relative to the set of mutant p53 tumors in each case. A
naïve Bayes (NB) classifier was then used for predictions
employing the top genes found by the T test. The classifi-
ers utilize the marginal frequencies of the outcome cases
in the training set when making out-of-sample predic-
tions. For in-sample predictions, a 3-fold validation was
repeated 10 times to arrive at the final predictions. These
algorithms were then used for predictions of out-of-sam-
ple sets, i.e. only early or only late stage cancers. Hierar-
chical clustering was performed on both probes and
samples using a Pearson centered similarity measure.
Probe lists used to make the naïve Bayes predictions can
be found in Additional File 2.
For comparing gene expression data between the
Affymetrix and Illumina DASL platforms, we tested for
correlation by calculating a Pearson coefficient and the
associated two-tailed P value.
Results
The entire coding sequence of TP53 was analyzed in a set
of 89 primary serous ovarian cancers comprised of 40
early stage (I/II) and 49 advanced stage (III/IV) cases
(Table 1). The overall mutation rate was 66% in this series
with a larger fraction of the early stage (78%) than late
stage cancers (57%) harboring amino acid changing alter-
ations (Table 2). The most common type of mutation led
to single amino acid substitutions (68% of mutations) and
the most common sites were in codons 220 and 273 (4
each) followed by 175 and 278 (3 each). Mutations that
are predicted to result in a premature chain termination
(referred to as "null") constituted 32% of the total. These
null mutations were far more common in the early stage
(38%) than late stage (8%) cancers (p = 0.003).
While outcome data is not available for the majority of
the early stage cancers, advanced stage cancers were from
a previously published cohort used to derive an expres-
sion signature related to disease survival [15]. These cases
were chosen to represent the extremes in outcome; one
set was derived from women who survived less than 3
years after diagnosis and the other set from women with
greater than 7 year survival from stage III/IV serous can-
cer. Mutations were much more prevalent in short term
survivors (21/26, 81%) than long term survivors (7/23,
30%, p = 0.0004). Of the mutations in advanced stage can-
cers, only two from each group (short and long term sur-
vivors) were null with the remainder being missense
changes. Therefore, the presence of a missense p53 muta-
tion in this data set is associated with poor prognosis.
Each of these tumors was previously analyzed for gene
expression using Affymetrix U133A arrays [15,16]. From
these data, we used p53 status to perform supervised
classification. As a general approach, we first filtered the
>22,000 probes sets by expression levels across all sam-
ples down to 13,622 probes for all subsequent analyses.
An unpaired T test was then applied to the expression
data using various categorical assignments of the ovarian
cancers by stage and p53 status. The genes found to be
most differentially expressed by the T tests were then
used for prediction modeling. Predictions were made by
naïve Bayes (NB) classifier with 3-fold validation repeated
10 times. The results of these T tests and predictions are
shown in Table 3. Finally, examples of hierarchical clus-
Table 1: Clinical Characteristics of Study Population
Early Stage (n = 40) Advanced Stage (n = 49)
Stage Number (%) Number (%)
IA 7 (17.5%)
IB 2 (5%)
IC 7 (17.5%)
IIA 1 (2.5%)
IIB 6 (15%)
IIC 17 (42.5%)
III 39 (79.6%)
IV 10 (20.4%)
Histological grade
Well differentiated 3 (7.5%) 2 (4.1%)
Moderately differentiated 9 (22.5%) 16 (32.6%)
Poorly differentiated 28 (70%) 31 (63.3%)Bernardini et al. BMC Cancer 2010, 10:237
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tering using these gene lists are shown in Figure 1 and in
Additional File 3.
Cancers were categorized by p53 status; all mutant ver-
sus wild type or specific class of mutation (missense or
null) versus wild type. We also sub-divided the cases by
stage (I/II and III/IV) to further refine and explore the
transcriptional signature related to p53 status. Analyzing
the entire cohort of 89 cancers using binary p53 status (all
mutant versus wild type), 9 probe sets were significant at
the 0.05 level after Benjamini-Hochberg multiple testing
correction. Using these probes, the mutational status of
77/89 (86.5%) cancers was correctly predicted. Of the 6
misclassified cancers that had sequencing verified muta-
tions, 5 were missense mutants and half were early stage.
Increasing the number of probes to 25 by decreasing the
stringency of the T test (p = 0.15) resulted in a less robust
predictor (13 cancers incorrectly assigned, 85.4%). The 9
probes represent 9 different genes (Table 4) and of these,
one has been related previously to p53; DDB2 (Damage
Specific DNA Binding Protein 2) [10,17]. Additional cate-
gories and results are given in Table 3. We used varying p
value thresholds for probe selection due to the absence of
probes significant at the 0.05 level. Nonetheless, predic-
tions in the training sets for each comparison were rea-
sonably accurate ranging from 86-96% correctly called
samples. Since only 4 advanced stage cases harbored p53
null mutations, comparisons using this group were not
performed.
Besides the binary mutant versus wild type comparison
for all stages, the only other comparison that yielded a set
(> 1) of probes significant at the 0.05 level was between
missense and null mutations. In this case, we set the
threshold at p = 0.02 which resulted in 241 probe sets.
The fact that most of the null mutations (15 of 19) were
found in early stage cancers could be an indication that
this comparison is confounded by disease stage.
Technical validation of the array data was accomplished
using a series of 38 of the advanced stage cancers that
were analyzed using the DASL platform from Illumina.
Of the 9 genes in the binary p53 signature (Table 4), 5
(including the 4 top genes) demonstrated significant cor-
relation between the two platforms (Additional File 4).
True validation of these signatures requires an indepen-
dent set of serous ovarian cancers with matching array
and sequencing data, however, no such data is available
thus far. Using our data set alone, a number of relevant
observations and tests can be made. This entails both
comparisons of gene sets and predictions from early to
advanced stage. Since all cancers in this study are of the
serous type, it is reasonable to expect that the effects of
p53 mutations should be similar in early and advanced
stage. Therefore, to test the robustness of the p53 signa-
tures, we compared probe lists derived separately from
early and late stage cancers. For binary mutation status
(wild type versus all mutant), the number of probes used
to build the prediction models were 42 for early and 68
for advanced cancers. One probe (CSNK1A1) was in
common between these lists (Table 3). Expanding to the
top 100 probes for each condition yielded an additional
common gene, TP53  itself. Finally, comparing the top
1000 probes gives 41 in common between early and late
stage. The number of common probes does not exceed
what might be found by chance (p = 0.36 for the intersec-
tion of the top 100 and p = 0.74 for the top 1000). The
same type of analysis for wild type versus only missense
mutations gave similar results. There are no probes in
common from the lists used for the prediction models
whereas 2 (DDB2 and AARSD1) of the top 100 and 46 of
the top 1000 probes are coincident in the signatures from
early and advanced cancers.
The small degree of overlap between probe sets sug-
gests that predictions made using the early stage signa-
ture would have a low accuracy when applied to the late
stage cancers and vice versa. Running the NB predictions
in this way yielded accuracy values of 48%, 55.6%, and
47.5% for three of the four combinations (indicated in
Table 5). However, when the model derived from early
stage cancers based upon binary p53 status was applied
to the group of late stage cancers, only 7/49 samples were
mis-classified for an accuracy of 85.7% (Figure 2). This is
appreciably better than chance and suggests that this sig-
nature may be the most biologically plausible. The genes
(Table 6, 42 probes from 42 different transcription units)
in this signature were compared to other published p53
Table 2: Distribution of TP53 mutations by cancer stage and type of mutation.
All Cancers Stage I/II Stage III/IV >7 yr Surv. <3 yr Surv
Wild Type 3 092 1 1 65
Missense 40 16 24 5 19
Null 19 15 4* 22
Total Mutations 59 (66.3%) 31 (77.5%) 28 (57%) 7 (30.4%) 21 (80.8%)**
* Null mutations as a fraction of total cases in early versus advanced cancers, p = 0.003
** Mutation rate in short versus long term survivors, p = 0.0004Bernardini et al. BMC Cancer 2010, 10:237
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Figure 1 Hierarchical clustering by both probes and samples. A) All 89 cancers from the study were clustered using the 9 probes derived from a 
global T test of differential expression between mutant and wild type cancers. Actual p53 status is indicated on the bar below the heatmap (mutant 
= red and wild type = blue). Red indicates high level expression. B) The 40 early stage cancers were clustered by binary p53 status using the top 42 
probe sets. Actual p53 status is indicated in the bar below the heatmap (mutant = red and wild type = blue).
 Bernardini et al. BMC Cancer 2010, 10:237
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signatures and transcriptionally related events. Three of
the genes (CDC2, DDB2, and TRIP13) were found by
Troester et al. in their p53 signature from breast cancer
[10] and DDB2 is now a well established p53 target gene
[17]. An additional three genes (ACTR2,  SAFB, and
PRC1) have been described as p53 transcriptional targets
with varying levels and types of evidence [18-20]. As a
comparison, of the 68 probes (representing 66 different
transcribed regions) derived from the advanced stage
cancers using binary p53 status, none have been identi-
fied in expression signatures or as p53 target genes.
Discussion
Mutations in the p53 gene are extremely common in epi-
thelial ovarian cancers, particularly those with serous his-
tology. Recent analyses of prophylactic salpingo-
oophorectomy specimens from BRCA1  carriers show
that the acquisition of these mutations may be a very
early event in the development of many cases [3,21,22].
Given the prevalence and potentially pivotal nature of
these mutations in the etiology of the disease, we sought
to define transcriptional patterns associated with p53
mutational status in a series of early and advanced serous
ovarian cancers. Since all cancers are of the serous histol-
ogy, this should serve to reduce false associations that
might arise in a study of mixed histologic types where the
prevalence of p53 mutations varies, i.e., patterns of
expression that are related to histology rather than the
disruption of p53 activity.
In a total of 89 cancers, we sequenced the entire p53
coding region and performed expression analysis using
Affymetrix U133A arrays. We categorized the cancers by
stage (40 stage I/II and 49 stage III/IV cancers). TP53
mutational status was considered as a binary (mutations
that alter the coding sequence versus wild type) and ter-
nary (premature chain terminating mutation, missense,
and wild type) variable to include possible differences in
biology between the types of mutation. The overall muta-
tion rate of 66% in this series is comparable to previous
studies that have sequenced the full coding sequence of
p53 in ovarian cancers [1,2,8,23-25]. Analyzed by stage,
mutations were more prevalent in the early stage cancers
(77% versus 63%) and the early stage cancers had a signif-
icantly higher incidence of null mutations (38% versus
8%). This is consistent with the report by Leitao et al. that
focused on early stage ovarian cancers [2]. In 21 early
Table 3: Results of T test and prediction modeling.
Comparison N Misclassified Accuracy # Probes P threshold #Probes < 0.05
Mutant v WT (all stages) 89 11 87.6% 9 ≤0.05 9
Missense v WT (all stages) 70 8 88.6% 21 ≤0.11 1
Missense v Null (all stages) 59 8 86.4% 29 ≤0.02 241
Mutant v WT (stage III/IV)) 49 5 89.8% 68 ≤0.14 0
Missense v WT (III/IV) 45 5 88.9% 17 ≤0.07 1
Mutant v WT (stage I/II) 40 4 90% 42 ≤0.36 0
Missense v WT (I/II) 25 1 96% 28 ≤0.85 0
Null v WT (I/II) 24 2 91.7% 889 ≤0.15 0
Table 4: Genes in binary p53 signature.
Gene Probe ID p-value Fold change* Prior evidence for p53 association
TJP3 35148_at 7.96E-07 1.19
DDB2 203409_at 1.44E-06 1.63 Yes
AARSD1 222064_s_at 8.10E-06 1.39
PLEKHM1 212717_at 9.21E-06 1.39
CXorf45 205583_s_at 1.82E-05 1.55
EZH1 32259_at 2.50E-05 1.35
FAM111A 218248_at 2.81E-05 1.27
MED16 43544_at 3.09E-05 1.33
CSNK1A1 208866_at 3.11E-05 1.26
* Fold change is relative to mutant p53 containing tumors, i.e., all of these probes were elevated in wild type.Bernardini et al. BMC Cancer 2010, 10:237
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stage serous cancers, 14 (67%) harbored mutations and of
these, 9 were chain terminating. Therefore, while the
mutation prevalence between early and late stage serous
cancers is comparable, the rate of null mutations is signif-
icantly different (p < 0.001 for the combined data from
Leitao et al. and our current study). Since mutations are
not likely to be lost during disease progression, the high
frequency of null mutations in the early stage cancers
may be an indication of differences in molecular patho-
genesis relative to advanced cancers. Whether this is also
related to the more favorable clinical outcome of early
stage cancers is unknown.
We broadly categorized p53 mutations as either prema-
t u r e  c h a i n  t e r m i n a t i n g  ( n u l l )  o r  m i s s e n s e  i n  o u r  g e n e
expression analysis. Beyond the incidence of these muta-
tions in early and advanced ovarian cancers, there is a sig-
n i f i c a n t  a m o u n t  o f  e v i d e n c e  i n d i c a t i n g  t h a t  i n c r e a s e d
stability of missense p53 mutant proteins and subsequent
accumulation in the nucleus leads to various transcrip-
tional and biological consequences over and above what
is seen when the protein is absent (as is the case with
most chain terminating mutations) [26-28].
Several studies correlated the type of p53 mutation
with clinical variables of epithelial ovarian cancers. Sood
et al. examined the presence of distant metastases (paren-
chyma of the liver or spleen or extra-abdominal) in rela-
tion to p53 mutations [8]. The most significant finding
was that distant metastasis was 8-fold more common in
patients with cancers that carried null mutations com-
pared to those with either missense mutations or wild
type p53. In addition, Shahin et al. found that ovarian
cancers with null mutations and functionally null tumors
(based upon lack of p53 immunostaining) had the worst
prognosis [25]. Therefore, two independent studies found
that null mutations, at least in advanced stage cancers,
seem to confer a more aggressive biology related to
metastasis and outcome. While our current study was not
s p e c i f i c a l l y  d e s i g n e d  t o  t e s t  d i s e a s e  o u t c o m e ,  t h e
advanced stage cancers were derived from women who
survived less than 3 years after initial diagnosis (n = 26)
and those who survived greater than 7 years (n = 23) [16].
Comparing mutation status to outcome in our advanced
stage cases, the overall prevalence of mutations was sig-
nificantly higher in the short term survivors (81% versus
30%) and both the long and short term survivor groups
contained 2 cancers with null mutations. Therefore, while
mutation status does correlate with survival in our series
of advanced stage cancers, the primary difference is in the
rate of missense mutations. A consistent and reproduc-
ible association between p53 mutations and ovarian can-
cer outcome remains elusive.
The primary goal of the current study was to determine
whether a gene expression signature related to p53 status
exists in ovarian cancer and could provide molecular
insight into the disease. To our knowledge, this is the first
exercise of its type applied to epithelial ovarian cancer
but similar studies have been published for other cancers.
Further, there is a large literature on transcriptional tar-
gets of p53 activity. Therefore, our study can be placed
judiciously into this broader context. In the present study,
using standard analytic approaches, gene lists of varying
significance were derived between groups of tumors
based on p53 status. A comparison of TP53 wild type ver-
Figure 2 Class prediction of binary p53 mutation status in ad-
vanced cancers using the algorithm derived from the binary sta-
tus of early stage cancers. The X axis is a measure of the confidence 
of the predictor for class assignment. Four mutant and three wild type 
tumors were mis-predicted. True mutational status is indicated by the 
symbols.
Table 5: Intersection of p53 probes between early and advanced cancers.
Mutant v Wild Type Missense v Wild Type
Stage # probes* Common Top 100** 1000** # probes Common Top 100 1000
Early 42 28
12 4 1 0 2 4 6
Advanced 68 17
* Number of probes used for prediction modeling from Table 2
** The intersection of the top 100/1000 probe sets from early and advanced cancersBernardini et al. BMC Cancer 2010, 10:237
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Table 6: Genes in early stage binary p53 signature.
Gene Probe ID p-value Fold change* Prior evidence 
for p53 association
Intersect with genes from Table 4
DDB2 203409_at 7.89E-05 1.56 Yes Yes
SLBP 206052_s_at 1.05E-04 0.44
TTC38 218272_at 1.41E-04 1.33
TRADD 205641_s_at 1.87E-04 1.33
FLJ21865 220349_s_at 1.93E-04 1.39
LTB4R 216388_s_at 2.18E-04 1.28
CYB561 207986_x_at 2.42E-04 1.26
GOLT1B 218193_s_at 2.53E-04 0.62
SQSTM1 220341_s_at 2.56E-04 1.37
PAPD4 222282_at 2.68E-04 1.41
RHEB 201453_x_at 3.11E-04 0.52
PACS1 220557_s_at 3.60E-04 1.35
TRIP13 204033_at 3.72E-04 0.59 Yes
P2RY5 218589_at 3.76E-04 1.88
SYNCRIP 209024_s_at 3.95E-04 0.64
ACTR2 200728_at 4.33E-04 0.60 Yes
PLEKHM1 212717_at 4.88E-04 1.37 Yes
TJP3 35148_at 4.88E-04 1.71 Yes
RAB22A 218360_at 5.07E-04 0.68
PARN 203905_at 5.51E-04 0.71
DFNB31 221887_s_at 5.59E-04 1.29
CHCHD8 220647_s_at 6.41E-04 0.70
EGFL8 208469_s_at 6.52E-04 1.34
ZRSR2 208174_x_at 7.50E-04 1.38
DRG2 203268_s_at 7.51E-04 1.27
ICMT 201611_s_at 8.01E-04 0.69
SMA4 206565_x_at 8.06E-04 1.59
GPC6 215387_x_at 8.60E-04 1.62
CRAT 209522_s_at 8.84E-04 1.43
PRC1 218009_s_at 8.86E-04 0.47 Yes
CSE1L 210766_s_at 9.46E-04 0.58
17p12 EST 216751_at 9.58E-04 1.46
MZF1 40569_at 9.64E-04 1.49
FANCI 213007_at 9.68E-04 0.60
ABCA7 219577_s_at 9.78E-04 1.36
SAFB 201748_s_at 9.79E-04 1.25 Yes
PFDN2 218336_at 9.87E-04 0.71
CDC2 203213_at 9.96E-04 0.54 Yes
FAM60A 220147_s_at 0.001024 0.62
STK38L 212572_at 0.001033 0.58
SF4 209547_s_at 0.001101 1.29
CSNK1A1 206562_s_at 0.001107 1.54 Yes
* Mean fold change is relative to mutant p53 containing tumorsBernardini et al. BMC Cancer 2010, 10:237
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sus mutant ovarian cancer of all stages yielded a set of 9
differentially expressed genes (at the p < 0.05 level using a
relatively stringent false discovery criterion). Within sam-
ple predictions using these 9 genes yields an accuracy of
86.5%. Of these 9 genes, only DDB2 has other experimen-
tal evidence indicating that it is a bona fide p53 target.
Transcription of DDB2 is activated by human p53 pro-
tein, the promoter element interacts with p53, it is part of
the xeroderma pigmentosum complementation group E
(XPE), and is involved in DNA damage recognition and
repair [17,29-32]. Further, this is one of the 52 genes
described by Troester et al. that discriminates breast can-
cers with p53 mutations. This gene appears to be a highly
plausible candidate for membership in a cancer associ-
ated p53 gene expression signature.
With no appropriate validation set yet available, the
strength of this overall predictor of TP53 mutation status
cannot be evaluated directly. However, we do present a
series of other predictors that can be tested within our
data set and related to other published p53 signatures. In
particular, the most robust approach within the con-
straints of the current study is to compare signatures
derived in early versus late stage disease. Since all cancers
were of serous histology, with relatively equal distribution
by grade, the biologic consequences of a p53 mutation
should be similar. Therefore, a signature derived on early
or late stage cancers and then applied to the remaining
cohort for "validation" should provide insight into the
strength of the predictor. We observed minimal overlap
in the gene sets that constitute these individual predictors
(Table 5) presaging a failure to validate. Indeed, for three
out of four of these predictors, accuracy in the validation
sets hovered around 50%. However, testing the gene set
derived from early stage cancers that were categorized by
binary p53 status on the set of advanced cancers resulted
in predictions with 86% accuracy. Examination of the
genes constituting this predictor provides further support
that this is a biologically meaningful result (Table 6). Of
the 42 genes in this list, 6 (DDB2, CDC2, TRIP13, ACTR2,
PCR1, and SAFB) have either been described in a p53
related breast cancer signature or implicated as p53 target
genes by other means. For comparison, there is a single
gene (MYBL2) in common between the two published
p53 breast cancer signatures and no genes in common
between either of the breast signatures and a similarly
derived colon cancer signature [9,10,33].
The primary confounder in discerning a clear expres-
sion signature of TP53 mutation may be the fundamental
importance of this pathway in the development of serous
ovarian cancers. In the current series, two thirds of the
cancers harbored p53 mutations. The question is whether
the remaining third have other alterations that result in
inactivation of downstream p53 functions. Numerous
mechanisms have been described that may impact on the
activity of p53 and there is no widely accepted metric for
evaluating this parameter, particularly from a frozen tis-
sue sample. Gene expression patterns indicative of muta-
tional status in ovarian cancers are discernible, but they
are not highly predictive in out of sample validation with
the exception of a signature developed specifically on
early stage cancers. However, a number of genes within
this signature have a high degree of biologic plausibility.
The confirmation of several of these genes in a p53
related breast cancer signature suggests that a core set of
expression markers could be developed to assess p53
activity in multiple cancer types.
Conclusions
Patterns of gene expression in serous ovarian cancers that
are characteristic of TP53 mutation can be discerned and
include several genes that are known p53 targets or have
been described in the context of expression signatures of
TP53 mutation in breast cancer. The high frequency of
mutations in these cancers, particularly in high grade dis-
ease, suggests that functional inactivation of this pathway
may be an obligate event.
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